Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer
Source: Businesswire India
Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876.
The confidential settlement resolves the pending litigation. “This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachurn, CEO of Medisca Pharmaceutique Inc. “We will continue to invest in more innovative products and solutions to meet our customers’ evolving needs globally and ensure that new and existing customers receive the high-quality products they deserve."
Medisca remains committed to protecting its intellectual property rights and proprietary technologies. Medisca has ongoing litigations against Fagron B.V., HiperScan GmbH, and Gako Deutschland GmbH for infringement of Medisca German counterpart patents. Those suits were filed in the Munich district court of Germany and request injunctions and monetary remedies.
About Medisca
Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty.
The Medisca MAZ® mixer provides an efficient, uniform, and high-quality solution for compounding hundreds of formulations and is protected by a robust portfolio of patents across the globe. As Partners in Wellness, Medisca offers an unfailing devotion to improving lives across a multitude of needs and people. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610770292/en/
DISCLAIMER
The content and services provided by Kalkine Consultancy India Private Limited (Research Analyst License No: INH000017727, hereinafter referred to as “Kalkine”) are for informational purposes only. The content, including but not limited to articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, charts, animations, and videos (collectively, “Content”), is a service of Kalkine Consultancy India Private Limited and is available for personal and non-commercial use only. Kalkine does not provide personalized financial advice and does not endorse or recommend any individuals, investment products, or services as suitable for specific financial situations. Investors are advised to consult a qualified financial planner or adviser to assess their risk tolerance and portfolio suitability before making any investment decisions. Kalkine accepts no liability for investment losses or any other financial detriment arising from reliance on the Content. Some of the Content on this website may be sourced from third-party providers. Kalkine does not claim ownership over such third-party content and does not guarantee its accuracy, completeness, or reliability. Kalkine shall not be held liable for any errors, omissions, or inaccuracies in third-party content or for any damages or losses resulting from its use. Any images, music, or videos used in the Content are either sourced from publicly available materials, paid subscriptions, or credited to their respective owners where applicable. Kalkine does not claim ownership of third-party media unless explicitly stated. This disclaimer is subject to change without notice. Users are advised to review it periodically for updates.